Company news

Neurizon Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Appendix 4C - Quarterly Report & Company Update - March 2017

April 13, 2017

Dr Richard Hopkins Appointed as CEO of PharmAust

February 28, 2017

Appendix 4D & Financial Report - Dec 2016

February 28, 2017

Appendix 4C - Quarterly Report & Company Update

January 31, 2017

PharmAust Receives $406K R&D Rebate from ATO

January 30, 2017

Phase II Strategy Update

November 20, 2016

Phase II Canine Trial begins at University of Cambridge

September 18, 2016

Epichem achieves ISO 9001 2015 certification

September 15, 2016

MPL capsules shipped to centres in NSW & Qld for Phase II

September 12, 2016

Appendix 4E & Full Year Statutory Accounts 2016

August 31, 2016

Further Canine Trials to be Initiated in Australia

August 9, 2016

IP exchange with UNSW consolidates MPL patent position

August 2, 2016

Appendix 4C Quarterly & Brief Company Update - June 2016

July 28, 2016

Reformulated MPL capsules completed, Phase II to commence

July 10, 2016

University of Cambridge to begin Phase II Trial

June 26, 2016

Epichem Successful in AusTrade Grant

June 15, 2016

Appendix 4C Quarterly Report & Brief Company Update

April 28, 2016

First Two Patients in Canine Clinical Trial Begin Treatment

March 30, 2016

Completion of Share Sale Agreement and Drilling Commenced

March 30, 2016

Placement & Offer to Purchase Pela Resources

March 30, 2016

PharmAust to acquire rights to 3 oncology product platforms

March 30, 2016

Clarification on Record Date for SPP

March 30, 2016

Appendix 4D / Half Year Financial Report

March 30, 2016

Appendix 4D and Financial Report Dec 2012

March 30, 2016

PharmAust Fully Executes Share Sale Agreement With Pitney

March 30, 2016

Key Licence Provided by NewSouth Innovations

March 30, 2016

Important Discovery in Cancer Therapy

March 30, 2016

Clinical Study with PPL-1 Initiated following Approval

March 30, 2016

Appendix 4C - Quarterly

March 30, 2016

Appendix 4C

March 30, 2016

Human Cancer Trial Advancing To Second Patient

March 30, 2016

Clinical Trial in Dogs is now open for accrual

March 30, 2016

Appendix 4C Quarterly & Company Update

March 30, 2016

Strategy for Phase II Clinical Trial of Monepantel

March 7, 2016

Appendix 4D & Half Yearly Report and Accounts

February 28, 2016

Notice of Allowance received from USA Patent OffIce

February 11, 2016

Treatment of Canine Cancers

February 10, 2016

SPP Shortfall Heaily Oversubscribed

February 10, 2016

Share Sale Deed executed for the sale of Pela Resources

February 10, 2016

Shareholder Update - Human & Canine Trials

February 10, 2016

Second Dog Shows Suppression of Cancer Marker at Days 3 & 7

February 10, 2016

Second Cancer Patient Completes Course With Stable Disease

February 10, 2016

Response to ASX Volume Query

February 10, 2016

Response to ASX Price Query

February 10, 2016

Research Collaboration & Joint Patent with Japanese Company

February 10, 2016

Reduction of further Cancer Marker confirmed in Human Trial

February 10, 2016

Quarterly Report & Company Update

February 10, 2016

Placement

February 10, 2016

Phase I Trial at RAH Meets Safety & Cancer Marker End Points

February 10, 2016

PharmAust Receives $546K R&D Rebate from ATO

February 10, 2016

← Newer news releases · Older news releases →

Decks

The 5 newest of 37 decks. Every deck is listed under its year.